Charehbili A, de Groot S, van der Straaten T, Swen J J, Pijl H, Gelderblom H, van de Velde C J H, Nortier J W R, Guchelaar H J, Kroep J R
Department of Medical Oncology, Leiden University Medical Center, PO Box 9600, Albinusdreef 2, 2300 RC Leiden, The Netherlands.
Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Pharmacogenomics. 2015;16(11):1267-76. doi: 10.2217/PGS.15.74. Epub 2015 Aug 20.
SNPs may be associated with (side) effects of chemotherapy and may be useful as biomarkers to predict febrile neutropenia.
PATIENTS & METHODS: 187 DNA samples extracted from formalin-fixed paraffin-embedded tissue from patients with stage II/III HER2-negative breast cancer were genotyped.
Candidate SNPs were selected and explored for association with febrile neutropenia and/or pathological complete response. TT genotype of 388 C>T in FGFR4 (rs351855) had a tendency toward higher incidence of febrile neutropenia during neoadjuvant chemotherapy, compared with the CT (p = 0.383) genotype and compared with the CC genotype (p = 0.068).
The TT genotype of 388 C>T FGFR4 may be related to incidence of febrile neutropenia during neoadjuvant TAC (docetaxel, doxorubicin, cyclophosphamide) chemotherapy and is possibly useful as a patient-related risk factor when assessing febrile neutropenia risk. Original submitted 23 January 2015; Revision submitted 26 May 2015.
单核苷酸多态性（SNPs）可能与化疗（副）作用相关，并且可用作预测发热性中性粒细胞减少症的生物标志物。
对187份从II/III期HER2阴性乳腺癌患者的福尔马林固定石蜡包埋组织中提取的DNA样本进行基因分型。
选择并探究了候选单核苷酸多态性与发热性中性粒细胞减少症和/或病理完全缓解的相关性。与CT基因型（p = 0.383）和CC基因型（p = 0.068）相比，FGFR4基因中388C>T（rs351855）的TT基因型在新辅助化疗期间有发热性中性粒细胞减少症发生率更高的趋势。
FGFR4基因388C>T的TT基因型可能与新辅助TAC（多西他赛、阿霉素、环磷酰胺）化疗期间发热性中性粒细胞减少症的发生率有关，并且在评估发热性中性粒细胞减少症风险时可能作为与患者相关的风险因素。原始稿件于2015年1月23日提交；修订稿件于2015年5月26日提交。
Zotero 插件